Posted by Michael Wonder on 07 Aug 2024
George Medicines files new drug application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase 3 development program
6 August 2024 - Two international Phase 3 clinical trials for the treatment of hypertension, versus dual therapy and placebo, met all primary efficacy and safety endpoints.
George Medicines today announces its submission to the US FDA of a new drug application for GMRx2, George Medicines’ lead pipeline candidate for the treatment for hypertension, including initiation of treatment.
